A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib

作者:Ju, Lixia*; Han, Mingquan; Su, Jinmei; Wu, Chunyan; Dong, Zhengwei
来源:Cancer Chemotherapy and Pharmacology, 2018, 82(3): 561-564.
DOI:10.1007/s00280-018-3660-2

摘要

It is widely known that ROS1 rearrangement mostly occurs in the adenocarcinoma subtype of non-small-cell lung cancer. Patients with squamous cell carcinoma harboring ROS1 rearrangement are extremely rare. This is a case report of a squamous cell carcinoma patient with ROS1 rearrangement. An 84-year-old Chinese woman with a about 6.6 cm mass in the right middle lobe and right pleural effusion, enlarged mediastinal and hilar lymph nodes was diagnosed with stage IIIB lung squamous cell carcinoma harboring ROS1 rearrangement is highly sensitive to crizotinib in the first treatment setting. This is the first time to report lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib. We hope that oncologists will notice this phenomenon and it will help the lung squamous cell carcinoma patient to get longer overall survival time.

  • 出版日期2018-9
  • 单位同济大学附属上海市肺科医院; 同济大学

全文